Sort
30,917 grants matching “tumor microenvironment”
REWIRING SUPPRESSIVE TUMOR MICROENVIRONMENT SIGNALS FOR IMMUNE ACTIVATION USING T CELLS ENGINEERED WITH SYNTHETIC PROMOTERS
$747,221Massachusetts Institute Of Technology · · FY2021 · Defense Health Agency
Mechanisms of pathogenesis in patient derived organoid models of prostate cancer
$747,170Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress
$746,835Christopher D Willey · University Of Alabama At Birmingham · U01 · FY2019 · CA
Using implantable microdevices for deep phenotyping of multiple drug responses in brain tumor patients
$746,821Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2023 · CA
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma
$746,809Stephen C Mack · St. Jude Children'S Research Hospital · U01 · FY2024 · CA
Microenvironmental regulation of glioblastoma radiosensitivity
$746,706Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
An organotypic model recapitulating colon cancer microenvironment and metastasis
$746,690Emina Hui-Na Huang · Cleveland Clinic Lerner Com-Cwru · U01 · FY2019 · CA
Preclinical drug development in pancreas cancer
$746,546Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Vevo 3100 ultrasound scanner and PV loop system
$746,509Flemming Forsberg · Thomas Jefferson University · S10 · FY2021 · OD
Clinical Protocol and Data Management
$746,042Scott Michael Schuetze · University Of Michigan At Ann Arbor · P30 · FY2024 · CA
The Pacific Northwest Prostate Cancer SPORE
$745,961Peter S Nelson · Fred Hutchinson Cancer Research Center · P50 · FY2016 · CA
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
$745,842Paul M. Lieberman · Wistar Institute · R01 · FY2023 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$745,334Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2021 · DE
Understanding omega-3 and 6 fatty acid dependent regulation of inflammatory signals in pancreatic cancer
$745,320Susan M Kaech · Salk Institute For Biological Studies · U01 · FY2025 · CA
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
$745,005Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
$744,819Wei-Jun Qian · Battelle Pacific Northwest Laboratories · R01 · FY2020 · DK
Synthetic circuit technologies for precision control and signal processing in mammalian cells
$744,685Ahmad Samir Khalil · Boston University (Charles River Campus) · R01 · FY2025 · EB
Tumor stem cells and metastatic outcomes in mouse models of prostate cancer
$744,376Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Nitric Oxide as a Modifier of Oxidative Stress
$743,717David Wink · Division Of Clinical Sciences - Nci · ZIA · FY2025 · CA
Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated Malignancies
$743,574Yoshihiro Izumiya · University Of California At Davis · R01 · FY2020 · CA
Cell density effects on therapeutic sensitivity
$743,010Jayne Stommel · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments
$742,970Melissa Lambeth Kemp · Georgia Institute Of Technology · U01 · FY2020 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
$742,887Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2024 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
$742,887Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2025 · CA
REPROGRAMMING THE TUMOR MICROENVIRONMENT TO IMPROVE HEARING AND TREATMENT EFFICACY IN NF2 VESTIBULAR SCHWANNOMA.
$742,819The General Hospital Corporation · · FY2020 · Defense Health Agency